We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
PEGASYS peginterferon alfa-2a 135 micrograms/0.5mL injection pre-filled syringe (Ireland)
Section 19A approved medicine
PEGASYS peginterferon alfa-2a 135 micrograms/0.5mL injection pre-filled syringe (Ireland)
Section 19A approval holder
Echo Therapeutics Pty Ltd ABN 92 628 298 699
Phone
1300 848 328
Approved until
Status
Current
Medicines in short supply/unavailable
PEGASYS peginterferon alfa-2a 135 micrograms/0.5mL injection pre-filled syringe - ARTG 91836
Indication(s)
Chronic Hepatitis C (CHC)
The combination of Pegasys and ribavirin is indicated for the treatment of chronic hepatitis C in patients who have received no prior interferon therapy (treatment-naïve patients) and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin.
The combination of Pegasys and ribavirin is also indicated for the treatment of chronic hepatitis C patients with clinically stable human immunodeficiency virus (HIV) co-infection who have previously not received interferon therapy.
Pegasys monotherapy is indicated for the treatment of chronic hepatitis C in treatment-naïve patients.
Patients must be 18 years of age or older and have compensated liver disease.
Chronic Hepatitis B (CHB)
PEGASYS is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and liver inflammation and compensated liver disease.
Images
